Evaluation of Continuous Inhaled Epoprostenol in the Treatment of Acute Respiratory Distress Syndrome, Including Patients With SARS-CoV-2 Infection.

Hannah L NissAdham M MohamedTimothy P BerryTimothy M SaetteleMichelle M HainesElizabeth L Thomas

Published in: The Annals of pharmacotherapy (2022)

iEPO was associated with a positive effect in a majority of moderate-to-severe ARDS patients, including patients with SARS-CoV-2-related ARDS. Lower baseline PF and non-SARS-CoV-2-related ARDS were significantly associated with a positive response to iEPO. The ability to predict which patients will respond to iEPO can facilitate better utilization.

Keyphrases

acute respiratory distress syndrome
sars cov
extracorporeal membrane oxygenation
mechanical ventilation
ejection fraction
newly diagnosed
prognostic factors
respiratory syndrome coronavirus
coronavirus disease
high intensity
patient reported
drug induced